Haba Laboratories Inc. said its normalized net income for the fiscal fourth quarter ended March 31 came to ¥79.28 per share, a decrease of 11.1% from ¥89.13 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥311.9 million, a decrease of 11.1% from ¥350.6 million in the prior-year period.
The normalized profit margin declined to 8.0% from 8.8% in the year-earlier period.
Total revenue decreased year over year to ¥3.90 billion from ¥3.96 billion, and total operating expenses totaled ¥3.39 billion, compared with ¥3.40 billion in the prior-year period.
Reported net income declined 64.4% on an annual basis to ¥217.0 million, or ¥55.16 per share, from ¥610.0 million, or ¥155.07 per share.
For the year, the company's normalized net income totaled ¥38.61 per share, a decline of 79.9% from ¥191.77 per share in the prior year.
Normalized net income was ¥151.9 million, a decline of 79.9% from ¥754.4 million in the prior year.
Full-year total revenue decreased on an annual basis to ¥13.18 billion from ¥13.79 billion, and total operating expenses grew on an annual basis to ¥12.90 billion from ¥12.53 billion.
The company said reported net income fell 95.2% on an annual basis to ¥44.0 million, or ¥11.19 per share, in the full year, from ¥916.0 million, or ¥232.86 per share.
As of June 22, US$1 was equivalent to ¥123.23.